Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of metastasis-directed therapy for metachronous thoracic metastases following definitive (chemo)radiotherapy in p16-positive head and neck squamous cell carcinoma.

Oral oncology·2026
Same author

Quality of Life in Patients With p16+ Oropharyngeal Cancer Receiving Accelerated Radiation Therapy With Either Cisplatin or Cetuximab in the NRG/RTOG 1016 Randomized Controlled Trial.

International journal of radiation oncology, biology, physics·2026
Same author

Integrity of delivered dose in temporally fractionated lattice radiotherapy amid anatomical changes and setup uncertainties.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Reirradiation Collaborative Group (ReCOG) consensus on standards for dose evaluation and reporting in patients with multiple courses of radiation therapy: an AAPM/ACRO/ASTRO/CARO/COMP/CADRA/CPQR/ESTRO/NRG-endorsed consensus statement.

The Lancet. Oncology·2026
Same author

Prospective evaluation of liver cancer volumes on non-contrast 1.5 T MR Linac imaging.

Clinical and translational radiation oncology·2026
Same author

Pembrolizumab and stereotactic body radiotherapy combined in advanced hepatocellular carcinoma post sorafenib - A phase II trial (PEMRAD).

JHEP reports : innovation in hepatology·2026

Related Experiment Video

Updated: Jul 13, 2026

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Upper abdominal malignancies: intensity-modulated radiation therapy.

Mojgan Taremi1, Jolie Ringash, Laura A Dawson

  • 1Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto , Canada.

Frontiers of Radiation Therapy and Oncology
|July 21, 2007
PubMed
Summary

Intensity-modulated radiation therapy (IMRT) shows promise for upper abdominal cancers, but motion degrades plans. Combining IMRT with motion reduction and image guidance is crucial for future clinical trials.

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

Related Experiment Videos

Last Updated: Jul 13, 2026

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

Area of Science:

  • Oncology
  • Radiation Oncology
  • Medical Physics

Background:

  • Upper abdominal malignancies have poor prognoses, with challenges in delivering effective radiation therapy due to organ motion and sensitive surrounding tissues.
  • Intensity-modulated radiation therapy (IMRT) offers potential for dose escalation and improved normal tissue sparing in treating these tumors.
  • Existing studies indicate that while IMRT planning shows promise, its effectiveness can be compromised by organ motion in the upper abdomen.

Purpose of the Study:

  • To evaluate the potential of Intensity-modulated radiation therapy (IMRT) for improving local control and survival in upper abdominal malignancies.
  • To address the challenges of organ motion and normal tissue tolerance in radiation therapy for upper abdominal cancers.
  • To explore the integration of IMRT with motion reduction and image guidance strategies.

Main Methods:

  • Review of planning studies investigating Intensity-modulated radiation therapy (IMRT) for upper abdominal tumors.
  • Analysis of factors contributing to the degradation of IMRT plans, specifically organ motion.
  • Discussion of the necessity for organ motion reduction and image guidance techniques alongside IMRT.

Main Results:

  • Intensity-modulated radiation therapy (IMRT) planning studies demonstrate the potential for dose escalation to upper abdominal tumors.
  • Organ motion significantly degrades the quality and effectiveness of Intensity-modulated radiation therapy (IMRT) plans in the upper abdomen.
  • Clinical experience with dose-escalated IMRT for these malignancies is currently limited.

Conclusions:

  • Intensity-modulated radiation therapy (IMRT) holds promise for treating upper abdominal malignancies but requires strategies to mitigate motion-related planning degradation.
  • The combination of IMRT with organ motion reduction and image guidance is essential for its effective clinical application.
  • Further investigation through clinical trials is necessary before routine adoption of dose-escalated IMRT for upper abdominal cancers.